MedTrace Logo

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

NCT06434350 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-03-02

No results posted yet for this study

Summary

To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.

Conditions

  • Advanced Bladder Cancer

Interventions

DRUG

Enfortumab Vedotin

Given by IV

RADIATION

Radiation Therapy

Given by Radiation Therapy

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Comron Hassanzadeh, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-10
Primary Completion
2027-09-24
Completion
2027-09-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06434350 on ClinicalTrials.gov